Hyderabad, India; 24 th June 2020: Following the approval of ‘COVIFOR’, the generic of Remdesivir by DCGI, Hetero Healthcare Limited, a group company of Hetero is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week’s time, in order to meet the emergency requirements. The product is priced at Rs. 5,400/- per vial.
Mr. M. Srinivasa Reddy, Managing Director, Hetero Healthcare Limited said: “The launch of COVIFOR in India is a significant milestone for all of us. Hetero Healthcare has always been at the forefront in addressing the public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating covid-19 infection rates. We are working closely with the Government and Medical Community to make ‘Covifor’ quickly accessible to both public and private healthcare settings across the country.”
Covifor is the first generic brand of Remdesivir which is indicated for the treatment of COVID19 patients in adults and children, hospitalized with severe symptoms of the disease. The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner. Covifor is anticipated to play a significant role in bringing down the mortality rates caused by Covid-19, given its proven positive clinical outcomes
The forum has raised the bar on role of biosimilars in addressing the challenges in treating complicated solid and blood cancers.
It was bi way interactive concourse, with doctors of multiple regions expressing their ways of practice, presenting real time experience in treating cancers. The hearing served as an eye opener for many of the upcoming and practicing oncologists on importance of addition of biosimilars in treatment protocols
Indeed, it was Hetero Biopharma’s team effort put in by field force and strategic business partners to bring the doctors, onto this virtual platform to utilise this lock down period in learning updated treatment modalities in cancer therapy. We are glad to announce further sessions are lined up in fields of Nephrology and Rheumatology..